Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease

被引：19

作者：

Patterson, C. E. ^{[2
]}

Todd, S. A. ^{[1
,2
]}

Passmore, A. P. ^{[1
,2
]}

机构：

[1] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Belfast BT9 7BL, Antrim, North Ireland

[2] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland

来源：

PHARMACOGENOMICS JOURNAL | 2011年 / 11卷 / 06期

关键词：

Alzheimer's disease; apolipoprotein E; butyrylcholinesterase; cholinesterase inhibitor; E EPSILON-4 ALLELE; MINI-MENTAL-STATE; K-VARIANT; APOE GENOTYPE; TEMPORAL CORTEX; TACRINE THERAPY; ONSET; DONEPEZIL; ASSOCIATION; DEMENTIA;

D O I：

10.1038/tpj.2010.61

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Factors that influence response to drug treatment are of increasing importance. We report an analysis of genetic factors affecting response to cholinesterase inhibitor therapy in 165 subjects with Alzheimer's disease (AD). The presence of apolipoprotein E epsilon 4 (APOE epsilon 4) allele was associated with early and late cognitive response to cholinesterase inhibitor treatment in mild AD (Mini-Mental State Examination (MMSE) >= 21) (P<0.01). In moderate-to-severe AD (MMSE <= 15), presence of the BCHE-K variant was associated with late response to cholinesterase inhibitor treatment (P = 0.02). Testing for APOE and BCHE genotypes may be useful in therapeutic decision making. The Pharmacogenomics Journal (2011) 11, 444-450; doi:10.1038/tpj.2010.61; published online 20 July 2010

引用

页码：444 / 450

页数：7

共 69 条

[21] Metrifonate treatment of AD -: Influence of APOE genotype [J].

Farlow, MR ;

Cyrus, PA ;

Nadel, A ;

Lahiri, DK ;

Brashear, A ;

Gulanski, B .

NEUROLOGY, 1999, 53 (09) :2010-2016

[22] Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease [J].

Farlow, MR ;

Lahiri, DK ;

Poirier, J ;

Davignon, J ;

Schneider, L ;

Hui, SL .

NEUROLOGY, 1998, 50 (03) :669-677

[23] Apolipoprotein E genotype and gender influence response to tacrine therapy [J].

Farlow, MR ;

Lahiri, DK ;

Poirier, J ;

Davignon, J ;

Hui, S .

APOLIPOPROTEIN E GENOTYPING IN ALZHEIMER'S DISEASE, 1996, 802 :101-110

[24]

Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041

[25] Global prevalence of dementia: a Delphi consensus study [J].

Ferri, CP ;

Prince, M ;

Brayne, C ;

Brodaty, H ;

Fratiglioni, L ;

Ganguli, M ;

Hall, K ;

Hasegawa, K ;

Hendrie, H ;

Huang, YQ ;

Jorm, A ;

Mathers, C ;

Menezes, PR ;

Rimmer, E ;

Scazufca, M .

LANCET, 2005, 366 (9503) :2112-2117

[26] MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].

FOLSTEIN, MF ;

FOLSTEIN, SE ;

MCHUGH, PR .

JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198

[27] Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K) [J].

Grubber, JM ;

Saunders, AM ;

Crane-Gatherum, AR ;

Scott, WK ;

Martin, ER ;

Haynes, CS ;

Conneally, PM ;

Small, GW ;

Roses, AD ;

Haines, JL ;

Pericak-Vance, MA .

NEUROSCIENCE LETTERS, 1999, 269 (02) :115-119

[28]

HACHINSKI VC, 1974, LANCET, V2, P207

[29] Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation [J].

Holmes, C ;

Ballard, C ;

Lehmann, D ;

Smith, AD ;

Beaumont, H ;

Day, IN ;

Khan, MN ;

Lovestone, S ;

McCulley, M ;

Morris, CM ;

Munoz, DG ;

O'Brien, K ;

Russ, C ;

Del Ser, T ;

Warden, D .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (05) :640-643

[30] Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site [J].

Jensen, FS ;

Nielsen, LR ;

Schwartz, M .

HUMAN HEREDITY, 1996, 46 (01) :26-31

← 1 2 3 4 5 6 7 →